Abstract: Provided herein are chemical matrices, compositions, and methods for the treatment of skin diseases and disorders in an individual. Said chemical matrices and compositions comprise an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, a corticosteroid, wherein the alcohol is distributed within the chemical matrix as a microbubble and the corticosteroid is present in less than the standardized topical corticosteroid concentration. Additionally, methods are described for the use of said chemical matrices and compositions for the treatment of skin diseases and disorders.

Abstract: Provided herein are chemical matrices, compositions, methods and devices for the treatment of skin diseases and disorders in an individual. Described herein are non-homogenous chemical matrices and compositions comprising an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, optionally, at least one pharmaceutical agent, wherein the alcohol is distributed within the chemical matrix as a microbubble. Additionally, methods are described for the use of said chemical matrices and compositions for the treatment of skin diseases and disorders.

Abstract: Provided herein are chemical matrices, compositions, and methods for the treatment of skin diseases and disorders in an individual. Said chemical matrices and compositions comprise an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, a corticosteroid, wherein the alcohol is distributed within the chemical matrix as a microbubble and the corticosteroid is present in less than the standardized topical corticosteroid concentration. Additionally, methods are described for the use of said chemical matrices and compositions for the treatment of skin diseases and disorders.

Abstract: Provided herein are chemical matrices, compositions, and methods for the treatment of skin diseases and disorders in an individual. Said chemical matrices and compositions comprise an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, a corticosteroid, wherein the alcohol is distributed within the chemical matrix as a microbubble and the corticosteroid is present in less than the standardized topical corticosteroid concentration. Additionally, methods are described for the use of said chemical matrices and compositions for the treatment of skin diseases and disorders.

Abstract: Provided herein are chemical matrices, compositions, methods and devices for the treatment of skin diseases and disorders in an individual. Described herein are non-homogenous chemical matrices and compositions comprising an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, optionally, at least one pharmaceutical agent, wherein the alcohol is distributed within the chemical matrix as a microbubble. Additionally, methods are described for the use of said chemical matrices and compositions for the treatment of skin diseases and disorders.

Abstract: Provided herein are chemical matrices, compositions, methods and devices for the treatment of skin diseases and disorders in an individual. Described herein are non-homogenous chemical matrices and compositions comprising an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, optionally, at least one pharmaceutical agent, wherein the alcohol is distributed within the chemical matrix as a microbubble. Additionally, methods are described for the use of said chemical matrices and compositions for the treatment of skin diseases and disorders.

Abstract: Provided herein are chemical matrices, compositions, and methods for the treatment of skin diseases and disorders in an individual. Said chemical matrices and compositions comprise an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, a corticosteroid, wherein the alcohol is distributed within the chemical matrix as a microbubble and the corticosteroid is present in less than the standardized topical corticosteroid concentration. Additionally, methods are described for the use of said chemical matrices and compositions for the treatment of skin diseases and disorders.

Abstract: Provided herein are chemical matrices, compositions, methods and devices for the treatment of skin diseases and disorders in an individual. Described herein are non-homogenous chemical matrices and compositions comprising an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, optionally, at least one pharmaceutical agent, wherein the alcohol is distributed within the chemical matrix as a microbubble. Additionally, methods are described for the use of said chemical matrices and compositions for the treatment of skin diseases and disorders.

Abstract: Provided herein are compositions, methods and devices for the treatment of skin diseases and disorders in an individual. Described herein are pharmaceutical compositions comprising a non-homogenous vehicle, an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, optionally, at least one pharmaceutical agent. Additionally, methods are described for the use of said pharmaceutical compositions for the treatment of skin diseases and disorders, and devices are described for the preparation of said pharmaceutical compositions.

Abstract: Methods and kits for removing, treating or preventing head lice infestations in patients in need of such treatment are disclosed and include topically applying to the lice-infested area an effective amount of a driable pediculostatic agent for a time sufficient to immobilize the lice, drying the agent onto the application site and removing the dried agent, thereby removing the lice and nits.

Abstract: Methods and kits for removing, treating or preventing head lice infestations in patients in need of such treatment are disclosed and include topically applying to the lice-infested area an effective amount of a driable pediculostatic agent for a time sufficient to immobilize the lice, drying the agent onto the application site and removing the dried agent, thereby removing the lice and nits.

Abstract: Methods and kits for removing, treating or preventing head lice infestations in patients in need of such treatment are disclosed and include topically applying to the lice-infested area an effective amount of a driable pediculostatic agent for a time sufficient to immobilize the lice, drying the agent onto the application site and removing the dried agent, thereby removing the lice and nits.

Abstract: Methods and kits for removing, treating or preventing head lice infestations in patients in need of such treatment are disclosed and include topically applying to the lice-infested area an effective amount of a driable pediculostatic agent for a time sufficient to immobilize the lice, drying the agent onto the application site and removing the dried agent, thereby removing the lice and nits.

Abstract: Methods and kits for removing, treating or preventing head lice infestations in patients in need of such treatment are disclosed and include topically applying to the lice-infested area an effective amount of a driable pediculostatic agent for a time sufficient to immobilize the lice, drying the agent onto the application site and removing the dried agent, thereby removing the lice and nits.

Abstract: Methods and kits for removing, treating or preventing head lice infestations in patients in need of such treatment are disclosed and include topically applying to the lice-infested area an effective amount of a driable pediculostatic agent for a time sufficient to immobilize the lice, drying the agent onto the application site and removing the dried agent, thereby removing the lice and nits.

Abstract: A method for treating psoriasis comprising applying an effective amount of a cytotoxic drug dispersed in a pharmaceutically acceptable vehicle containing a penetrating solvent for the drug, the drug being applied to the skin area affected by the psoriasis without occlusion in pulses of from 1 to 3 applications per pulse, the pulses being applied at an interval of once every from 3 to 30 days and preferably at an interval of from 4 to 14 days. Optimally, the penetrating solvent is free from toxic effects, such as AZONE or similar substituted azacycloalkyl-2-ones, tertiary amine oxides, and the like.

Abstract: A method for treating actinic keratosis comprising applying an effective amount of a cytotoxic drug dispersed in a pharmaceutically acceptable vehicle containing a penetrating solvent for the drug, the drug being applied to the skin area having the actinic keratosis growth without occlusion in pulses at an interval of once every from 3 to 30 days and preferably at an interval of from 4 to 14 days. Optimally, the penetrating solvent is free from toxic effects, such as propylene glycol, AZONE.RTM. or similar substituted azacycloalkyl-2-ones, tertiary amine oxides, and the like.

Abstract: A method for treating actinic keratosis comprising applying an effective amount of a cytotoxic drug dispersed in a pharmaceutically acceptable vehicle containing a penetrating solvent for the drug, the drug being applied to the skin area having the actinic keratosis growth without occlusion in pulses at an interval of once every from 3 to 30 days and preferably at an interval of from 4 to 14 days. Optimally, the penetrating solvent is free from toxic effects, such as AZONE or similar substituted azacycloalkyl-2-ones, tertiary amine oxides, and the like.